Sign in

    Colleen Hussie

    Research Analyst at Baird

    Colleen Hussie is an equity research analyst at Baird, specializing in comprehensive coverage within the sector she focuses on, but there is no public evidence confirming her exact job title, specific companies covered, or quantifiable performance metrics. Available information does not confirm her full career history, prior firms, or year of joining Baird, nor does it provide details about her securities licenses or professional recognitions. Without further verified data from LinkedIn or industry databases, a complete performance record or list of companies and accolades cannot be confidently provided. This professional outline reflects the current limits of accessible public data as of August 2025.

    Colleen Hussie's questions to Coherus Oncology (CHRS) leadership

    Colleen Hussie's questions to Coherus Oncology (CHRS) leadership • Q2 2025

    Question

    Asked about the company's commercial investments in the community setting, potential data readouts from Loktorzi partnerships, and the enrollment status of the frontline HCC trial.

    Answer

    The company is using a multi-pronged approach (salesforce, digital, data) to penetrate the community market, which will take time, with peak sales expected in 3-4 years. They clarified that Loktorzi partnerships involve supplying the drug for trials, not out-licensing, and an update from a partner (STORM Therapeutics) could come next year. Enrollment for the HCC trial is on track for H1 2026 data, though responses may take time to mature.

    Ask Fintool Equity Research AI